These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 36548004)
1. T-Peak to T-End Interval for Prediction of Positive Response to Ajmaline Challenge Test in Suspected Brugada Syndrome Patients. Thapanasuta M; Chokesuwattanaskul R; Leelapatana P; Rungpradubvong V; Prechawat S Med Sci (Basel); 2022 Dec; 10(4):. PubMed ID: 36548004 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of type 1 Brugada ECG pattern after administration of Class 1C drugs in patients with type 1 myotonic dystrophy: Myotonic dystrophy as a part of the Brugada syndrome. Maury P; Audoubert M; Cintas P; Rollin A; Duparc A; Mondoly P; Chiriac AM; Acket B; Zhao X; Pasquié JL; Cardin C; Delay M; Sadron M; Carrié D; Galinier M; Davy JM; Arne-Bès MC; Raczka F Heart Rhythm; 2014 Oct; 11(10):1721-7. PubMed ID: 25016148 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Ajmaline and Procainamide Provocation Tests in the Diagnosis of Brugada Syndrome. Cheung CC; Mellor G; Deyell MW; Ensam B; Batchvarov V; Papadakis M; Roberts JD; Leather R; Sanatani S; Healey JS; Chauhan VS; Birnie DH; Champagne J; Angaran P; Klein GJ; Yee R; Simpson CS; Talajic M; Gardner M; Yeung-Lai-Wah JA; Chakrabarti S; Laksman ZW; Sharma S; Behr ER; Krahn AD JACC Clin Electrophysiol; 2019 Apr; 5(4):504-512. PubMed ID: 31000106 [TBL] [Abstract][Full Text] [Related]
4. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Wolpert C; Echternach C; Veltmann C; Antzelevitch C; Thomas GP; Spehl S; Streitner F; Kuschyk J; Schimpf R; Haase KK; Borggrefe M Heart Rhythm; 2005 Mar; 2(3):254-60. PubMed ID: 15851314 [TBL] [Abstract][Full Text] [Related]
5. Predicting cardiac electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk scores. Tadros R; Tan HL; ; El Mathari S; Kors JA; Postema PG; Lahrouchi N; Beekman L; Radivojkov-Blagojevic M; Amin AS; Meitinger T; Tanck MW; Wilde AA; Bezzina CR Eur Heart J; 2019 Oct; 40(37):3097-3107. PubMed ID: 31504448 [TBL] [Abstract][Full Text] [Related]
6. Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study. Hohmann S; Rudic B; Konrad T; Duncker D; König T; Tülümen E; Rostock T; Borggrefe M; Veltmann C Europace; 2017 Oct; 19(10):1723-1729. PubMed ID: 27915266 [TBL] [Abstract][Full Text] [Related]
7. Value of the sodium-channel blocker challenge in Brugada syndrome. Therasse D; Sacher F; Babuty D; Mabo P; Mansourati J; Kyndt F; Redon R; Schott JJ; Barc J; Probst V; Gourraud JB Int J Cardiol; 2017 Oct; 245():178-180. PubMed ID: 28784436 [TBL] [Abstract][Full Text] [Related]
8. Correlation of intracardiac electrogram with surface electrocardiogram in Brugada syndrome patients. Probst V; Sacher F; Derval N; Gourraud JB; Mabo P; Medkour F; Le Marec H; Gill J Europace; 2014 Jun; 16(6):908-13. PubMed ID: 24068444 [TBL] [Abstract][Full Text] [Related]
9. Should all individuals with a nondiagnostic Brugada-electrocardiogram undergo sodium-channel blocker test? Zorzi A; Migliore F; Marras E; Marinelli A; Baritussio A; Allocca G; Leoni L; Perazzolo Marra M; Basso C; Buja G; Thiene G; Iliceto S; Delise P; Corrado D Heart Rhythm; 2012 Jun; 9(6):909-16. PubMed ID: 22334153 [TBL] [Abstract][Full Text] [Related]
10. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. Shimizu W; Antzelevitch C; Suyama K; Kurita T; Taguchi A; Aihara N; Takaki H; Sunagawa K; Kamakura S J Cardiovasc Electrophysiol; 2000 Dec; 11(12):1320-9. PubMed ID: 11196553 [TBL] [Abstract][Full Text] [Related]
11. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Hong K; Brugada J; Oliva A; Berruezo-Sanchez A; Potenza D; Pollevick GD; Guerchicoff A; Matsuo K; Burashnikov E; Dumaine R; Towbin JA; Nesterenko V; Brugada P; Antzelevitch C; Brugada R Circulation; 2004 Nov; 110(19):3023-7. PubMed ID: 15520322 [TBL] [Abstract][Full Text] [Related]
12. Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not? Viskin S; Chorin E; Rosso R; Amin AS; Wilde AA Circulation; 2024 Aug; 150(8):642-650. PubMed ID: 39159224 [TBL] [Abstract][Full Text] [Related]
13. Local depolarization abnormalities are the dominant pathophysiologic mechanism for type 1 electrocardiogram in brugada syndrome a study of electrocardiograms, vectorcardiograms, and body surface potential maps during ajmaline provocation. Postema PG; van Dessel PF; Kors JA; Linnenbank AC; van Herpen G; Ritsema van Eck HJ; van Geloven N; de Bakker JM; Wilde AA; Tan HL J Am Coll Cardiol; 2010 Feb; 55(8):789-97. PubMed ID: 20170818 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of the effects of sodium channel blockade on the arrhythmogenic substrate of Brugada syndrome. Nademanee K; Veerakul G; Nogami A; Lou Q; Hocini M; Coronel R; Behr ER; Wilde A; Boukens BJ; Haissaguerre M Heart Rhythm; 2022 Mar; 19(3):407-416. PubMed ID: 34742919 [TBL] [Abstract][Full Text] [Related]
15. Novel CineECG Derived From Standard 12-Lead ECG Enables Right Ventricle Outflow Tract Localization of Electrical Substrate in Patients With Brugada Syndrome. van Dam PM; Locati ET; Ciconte G; Borrelli V; Heilbron F; Santinelli V; Vicedomini G; Monasky MM; Micaglio E; Giannelli L; Mecarocci V; Ćalović Ž; Anastasia L; Pappone C Circ Arrhythm Electrophysiol; 2020 Sep; 13(9):e008524. PubMed ID: 32755392 [TBL] [Abstract][Full Text] [Related]
16. Single oral flecainide dose to unmask type 1 Brugada syndrome electrocardiographic pattern. Dubner S; Azocar D; Gallino S; Cerantonio AR; Muryan S; Medrano J; Bruno C Ann Noninvasive Electrocardiol; 2013 May; 18(3):256-61. PubMed ID: 23714084 [TBL] [Abstract][Full Text] [Related]
17. [Doubts of the cardiologist regarding an electrocardiogram presenting QRS V1-V2 complexes with positive terminal wave and ST segment elevation. Consensus Conference promoted by the Italian Cardiology Society]. Oreto G; Corrado D; Delise P; Fedele F; Gaita F; Gentile F; Giustetto C; Michelucci A; Padeletti L; Priori S G Ital Cardiol (Rome); 2010 Nov; 11(11 Suppl 2):3S-22S. PubMed ID: 21361048 [TBL] [Abstract][Full Text] [Related]
18. Impact of SMART Pass filter in patients with ajmaline-induced Brugada syndrome and subcutaneous implantable cardioverter-defibrillator eligibility failure: results from a prospective multicentre study. Conte G; Cattaneo F; de Asmundis C; Berne P; Vicentini A; Namdar M; Scalone A; Klersy C; Caputo ML; Demarchi A; Özkartal T; Salghetti F; Casu G; Passarelli I; Mameli S; Shah D; Burri H; De Ferrari G; Brugada P; Auricchio A Europace; 2022 May; 24(5):845-854. PubMed ID: 34499723 [TBL] [Abstract][Full Text] [Related]
19. Usefulness of patient's history and non-invasive electrocardiographic parameters in prediction of ajmaline test results in patients with suspected Brugada syndrome. Uziębło-Życzkowska B; Gielerak G; Michałkiewicz D Arch Med Sci; 2014 Oct; 10(5):899-912. PubMed ID: 25395941 [TBL] [Abstract][Full Text] [Related]
20. Heart rate variability and microvolt T wave alternans changes during ajmaline test may predict prognosis in Brugada syndrome. Călburean PA; Pannone L; Sorgente A; Gauthey A; Monaco C; Strazdas A; Almorad A; Bisignani A; Bala G; Ramak R; Overeinder I; Ströker E; Pappaert G; Van Dooren S; de Ravel T; La Meir M; Brugada P; Sieira J; Chierchia GB; de Asmundis C Clin Auton Res; 2023 Feb; 33(1):51-62. PubMed ID: 36645559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]